Examination of the RPPA data from the TCGA KIRC project allowed us to assess the possibility that RCC could be divided into subclasses based on the relative activation of the MEK and mTOR pathways as well as evaluate their potential therapeutic significance [39]. This evidence concerns the gene MTOR and renal cell carcinoma.